Inhibition of WNT signaling by G007-LK, pyrvinium, or salinomycin prevents the clinical features of sclGVHD in the model of B10.D2 (H-2^d) → BALB/c (H-2^d). (A) Preventive treatment with G007-LK, pyrvinium, or salinomycin impeded weight loss after alloBMT and resulted in a significantly higher body weight (left panel). The clinical composite score for cutaneous cGVHD was lower in mice treated with G007-LK, pyrvinium, or salinomycin compared with sham-treated mice (right panel). (B) Representative trichrome stained images of murine sclGVHD skin (original magnification ×100). WNT inhibitors prevented the histological changes in the dermis in experimental sclGVHD. Dermal thickness is represented by vertical black lines. (C) WNT inhibitors reduced dermal thickening, decreased the hydroxyproline content in the murine skin, and diminished the differentiation of resting dermal fibroblasts into myofibroblasts compared with vehicle-treated mice with allogeneic transplantation. (D) Representative lung sections (original magnification ×200; Sirius Red stain). (E) Fibrotic area, hydroxyproline content, and myofibroblast counts of murine lung (n = 6 mice per group). *P < .5; **P < .05; ***P < .01.